359 related articles for article (PubMed ID: 15178639)
1. Origins of serum semicarbazide-sensitive amine oxidase.
Stolen CM; Yegutkin GG; Kurkijärvi R; Bono P; Alitalo K; Jalkanen S
Circ Res; 2004 Jul; 95(1):50-7. PubMed ID: 15178639
[TBL] [Abstract][Full Text] [Related]
2. Semicarbazide sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications.
Stolen CM; Madanat R; Marti L; Kari S; Yegutkin GG; Sariola H; Zorzano A; Jalkanen S
FASEB J; 2004 Apr; 18(6):702-4. PubMed ID: 14977883
[TBL] [Abstract][Full Text] [Related]
3. Semicarbazide-sensitive amine oxidase in transgenic mice with diabetes.
Gokturk C; Nordquist J; Sugimoto H; Forsberg-Nilsson K; Nilsson J; Oreland L
Biochem Biophys Res Commun; 2004 Dec; 325(3):1013-20. PubMed ID: 15541390
[TBL] [Abstract][Full Text] [Related]
4. Semicarbazide-sensitive amine oxidase (SSAO): from cell to circulation.
Boomsma F; Hut H; Bagghoe U; van der Houwen A; van den Meiracker A
Med Sci Monit; 2005 Apr; 11(4):RA122-6. PubMed ID: 15795708
[TBL] [Abstract][Full Text] [Related]
5. Anti-inflammatory effects of inhibiting the amine oxidase activity of semicarbazide-sensitive amine oxidase.
Salter-Cid LM; Wang E; O'Rourke AM; Miller A; Gao H; Huang L; Garcia A; Linnik MD
J Pharmacol Exp Ther; 2005 Nov; 315(2):553-62. PubMed ID: 16081681
[TBL] [Abstract][Full Text] [Related]
6. Vascular cell lines expressing SSAO/VAP-1: a new experimental tool to study its involvement in vascular diseases.
Solé M; Unzeta M
Biol Cell; 2011 Nov; 103(11):543-57. PubMed ID: 21819380
[TBL] [Abstract][Full Text] [Related]
7. SSAO/VAP-1 protein expression during mouse embryonic development.
Valente T; Solé M; Unzeta M
Dev Dyn; 2008 Sep; 237(9):2585-93. PubMed ID: 18729210
[TBL] [Abstract][Full Text] [Related]
8. Adipocytes release a soluble form of VAP-1/SSAO by a metalloprotease-dependent process and in a regulated manner.
Abella A; García-Vicente S; Viguerie N; Ros-Baró A; Camps M; Palacín M; Zorzano A; Marti L
Diabetologia; 2004 Mar; 47(3):429-438. PubMed ID: 14968297
[TBL] [Abstract][Full Text] [Related]
9. Adipogenesis-related increase of semicarbazide-sensitive amine oxidase and monoamine oxidase in human adipocytes.
Bour S; Daviaud D; Gres S; Lefort C; Prévot D; Zorzano A; Wabitsch M; Saulnier-Blache JS; Valet P; Carpéné C
Biochimie; 2007 Aug; 89(8):916-25. PubMed ID: 17400359
[TBL] [Abstract][Full Text] [Related]
10. A peptide inhibitor of vascular adhesion protein-1 (VAP-1) blocks leukocyte-endothelium interactions under shear stress.
Yegutkin GG; Salminen T; Koskinen K; Kurtis C; McPherson MJ; Jalkanen S; Salmi M
Eur J Immunol; 2004 Aug; 34(8):2276-85. PubMed ID: 15259025
[TBL] [Abstract][Full Text] [Related]
11. VAP-1/SSAO plasma activity and brain expression in human hemorrhagic stroke.
Hernandez-Guillamon M; Solé M; Delgado P; García-Bonilla L; Giralt D; Boada C; Penalba A; García S; Flores A; Ribó M; Alvarez-Sabin J; Ortega-Aznar A; Unzeta M; Montaner J
Cerebrovasc Dis; 2012; 33(1):55-63. PubMed ID: 22133888
[TBL] [Abstract][Full Text] [Related]
12. A structure-activity study to identify novel and efficient substrates of the human semicarbazide-sensitive amine oxidase/VAP-1 enzyme.
Bonaiuto E; Lunelli M; Scarpa M; Vettor R; Milan G; Di Paolo ML
Biochimie; 2010 Jul; 92(7):858-68. PubMed ID: 20298739
[TBL] [Abstract][Full Text] [Related]
13. Involvement of SSAO/VAP-1 in oxygen-glucose deprivation-mediated damage using the endothelial hSSAO/VAP-1-expressing cells as experimental model of cerebral ischemia.
Sun P; Solé M; Unzeta M
Cerebrovasc Dis; 2014; 37(3):171-80. PubMed ID: 24503888
[TBL] [Abstract][Full Text] [Related]
14. VAP-1, a novel molecule linked to endothelial damage and kidney function in kidney allograft recipients.
Koc-Zorawska E; Malyszko J; Malyszko JS; Mysliwiec M
Kidney Blood Press Res; 2012; 36(1):242-7. PubMed ID: 23154672
[TBL] [Abstract][Full Text] [Related]
15. Obesity of mice lacking VAP-1/SSAO by Aoc3 gene deletion is reproduced in mice expressing a mutated vascular adhesion protein-1 (VAP-1) devoid of amine oxidase activity.
Jargaud V; Bour S; Tercé F; Collet X; Valet P; Bouloumié A; Guillemot JC; Mauriège P; Jalkanen S; Stolen C; Salmi M; Smith DJ; Carpéné C
J Physiol Biochem; 2021 Feb; 77(1):141-154. PubMed ID: 32712883
[TBL] [Abstract][Full Text] [Related]
16. Change of serum vascular adhesion protein-1 after glucose loading correlates to carotid intima-medial thickness in non-diabetic subjects.
Li HY; Lin MS; Wei JN; Hung CS; Chiang FT; Lin CH; Hsu HC; Su CY; Wu MY; Smith DJ; Vainio J; Chen MF; Chuang LM
Clin Chim Acta; 2009 May; 403(1-2):97-101. PubMed ID: 19361461
[TBL] [Abstract][Full Text] [Related]
17. Circulating form of human vascular adhesion protein-1 (VAP-1): increased serum levels in inflammatory liver diseases.
Kurkijärvi R; Adams DH; Leino R; Möttönen T; Jalkanen S; Salmi M
J Immunol; 1998 Aug; 161(3):1549-57. PubMed ID: 9686623
[TBL] [Abstract][Full Text] [Related]
18. Inhibitor sensitivity of human serum and vascular semicarbazide-sensitive amine oxidases.
Mészáros Z; Csányi A; Vallus G; Szombathy T; Karádi I; Magyar K
Neurobiology (Bp); 2000; 8(2):215-23. PubMed ID: 11061216
[TBL] [Abstract][Full Text] [Related]
19. New efficient substrates for semicarbazide-sensitive amine oxidase/VAP-1 enzyme: analysis by SARs and computational docking.
Yraola F; García-Vicente S; Fernandez-Recio J; Albericio F; Zorzano A; Marti L; Royo M
J Med Chem; 2006 Oct; 49(21):6197-208. PubMed ID: 17034126
[TBL] [Abstract][Full Text] [Related]
20. Involvement of semicarbazide-sensitive amine oxidase-mediated deamination in lipopolysaccharide-induced pulmonary inflammation.
Yu PH; Lu LX; Fan H; Kazachkov M; Jiang ZJ; Jalkanen S; Stolen C
Am J Pathol; 2006 Mar; 168(3):718-26. PubMed ID: 16507887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
